Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Ascorbic Acid for TET2 Mutated MDS/AML
NCT03397173Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Mar 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ascorbic acid in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), Myeloproliferative Neoplasm (MPN), sponsored by Case Comprehensive Cancer Center. Started Mar 2018; status: completed.
02
Drugs
ascorbic acid
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT03397173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03397173.